Abstract
In chronic lymphocytic leukemia (CLL) patients with mutated IGHV, 3 recent studies have demonstrated prolonged progression-free survival (PFS) after treatment with fludarabine-cyclophosphamide-rituximab (FCR) chemoimmunotherapy. We performed a systematic review to assess the benefit of FCR for patients with CLL and identified 5 randomized trials that met our inclusion criteria. FCR improved complete remission, PFS and overall survival vs the comparator; median PFS was not reached in the subgroup of CLL patients with mutated IGHV.
© 2017 by The American Society of Hematology.
Publication types
-
Case Reports
-
Review
-
Systematic Review
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cyclophosphamide / therapeutic use
-
Disease-Free Survival
-
Female
-
Humans
-
Immunoglobulin Heavy Chains / genetics*
-
Immunoglobulin Variable Region / genetics*
-
Immunotherapy
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
-
Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
-
Middle Aged
-
Mutation / genetics*
-
Remission Induction*
-
Rituximab / therapeutic use
-
Time Factors
-
Vidarabine / analogs & derivatives
-
Vidarabine / therapeutic use
Substances
-
Immunoglobulin Heavy Chains
-
Immunoglobulin Variable Region
-
Rituximab
-
Cyclophosphamide
-
Vidarabine
-
fludarabine